Compare Stocks: INO, MRNA, PBYI, and LRMR

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
INO Inovio Pharmaceuticals	$1.20 +4.3%	$1.03	$0.56 ▼ $2.98	$124.08M	1.52	2.47 million shs	4.74 million shs
LRMR Larimar Therapeutics	$4.06 -6.0%	$3.76	$2.71 ▼ $6.42	$421.77M	0.81	2.79 million shs	869,305 shs
MRNA Moderna	$62.96 -2.3%	$62.04	$22.28 ▼ $85.60	$25.14B	0.91	8.60 million shs	4.30 million shs
PBYI Puma Biotechnology	$9.24 +4.8%	$8.02	$4.30 ▼ $9.40	$476.97M	1.22	346,564 shs	244,692 shs

7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
INO Inovio Pharmaceuticals	+5.50%	+56.17%	+2.68%	-5.74%	-38.17%
LRMR Larimar Therapeutics	-0.92%	+7.73%	+16.76%	+29.73%	+7.73%
MRNA Moderna	+1.80%	+7.77%	+4.27%	+40.99%	+130.05%
PBYI Puma Biotechnology	-0.11%	+1.50%	+3.40%	+29.52%	+53.93%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
INO Inovio Pharmaceuticals	$1.20 +4.3%	$1.03	$0.56 ▼ $2.98	$124.08M	1.52	2.47 million shs	4.74 million shs
LRMR Larimar Therapeutics	$4.06 -6.0%	$3.76	$2.71 ▼ $6.42	$421.77M	0.81	2.79 million shs	869,305 shs
MRNA Moderna	$62.96 -2.3%	$62.04	$22.28 ▼ $85.60	$25.14B	0.91	8.60 million shs	4.30 million shs
PBYI Puma Biotechnology	$9.24 +4.8%	$8.02	$4.30 ▼ $9.40	$476.97M	1.22	346,564 shs	244,692 shs

7 Stocks That Will Be Magnificent in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
INO Inovio Pharmaceuticals	+5.50%	+56.17%	+2.68%	-5.74%	-38.17%
LRMR Larimar Therapeutics	-0.92%	+7.73%	+16.76%	+29.73%	+7.73%
MRNA Moderna	+1.80%	+7.77%	+4.27%	+40.99%	+130.05%
PBYI Puma Biotechnology	-0.11%	+1.50%	+3.40%	+29.52%	+53.93%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
INO Inovio Pharmaceuticals	2.75	Moderate Buy	$3.17	163.89% Upside
LRMR Larimar Therapeutics	3.10	Buy	$11.67	187.36% Upside
MRNA Moderna	1.88	Reduce	$42.13	-33.08% Downside
PBYI Puma Biotechnology	2.00	Hold	$6.00	-35.06% Downside

Current Analyst Ratings Breakdown

Latest INO, MRNA, PBYI, and LRMR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/13/2026	INO Inovio Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/13/2026	INO Inovio Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral
8/13/2026	INO Inovio Pharmaceuticals	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Positive	$1.80 ➝ $3.00
8/12/2026	INO Inovio Pharmaceuticals	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
8/7/2026	PBYI Puma Biotechnology	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold (C)
8/7/2026	PBYI Puma Biotechnology	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Hold	$5.00 ➝ $6.00
8/5/2026	LRMR Larimar Therapeutics	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$12.00 ➝ $11.00
8/3/2026	MRNA Moderna	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
8/3/2026	MRNA Moderna	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
8/3/2026	MRNA Moderna	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$41.00 ➝ $60.00
8/3/2026	INO Inovio Pharmaceuticals	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$4.00

(Data available from 8/18/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
INO Inovio Pharmaceuticals	$60K	2,068.00	N/A	N/A	$0.36 per share	3.33
LRMR Larimar Therapeutics	N/A	N/A	N/A	N/A	$0.94 per share	N/A
MRNA Moderna	$2.21B	11.37	N/A	N/A	$22.14 per share	2.84
PBYI Puma Biotechnology	$228.40M	2.09	$0.87 per share	10.59	$2.59 per share	3.57

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
INO Inovio Pharmaceuticals	-$84.95M	-$0.91	N/A	N/A	N/A	N/A	-669.94%	-73.97%	N/A
LRMR Larimar Therapeutics	-$165.67M	-$1.95	N/A	N/A	N/A	N/A	-137.39%	-97.65%	11/5/2026 (Estimated)
MRNA Moderna	-$2.82B	-$7.99	N/A	N/A	N/A	-141.43%	-28.30%	-19.39%	11/5/2026 (Estimated)
PBYI Puma Biotechnology	$31.11M	$0.52	17.77	84.00	N/A	11.50%	20.76%	13.22%	11/5/2026 (Estimated)

Latest INO, MRNA, PBYI, and LRMR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2026	Q2 2026	INO Inovio Pharmaceuticals	-$0.2167	-$0.07	+$0.1467	-$0.07	$0.53 million	N/A
8/6/2026	Q2 2026	PBYI Puma Biotechnology	$0.04	$0.19	+$0.15	$0.16	$53.00 million	$56.50 million
8/4/2026	Q2 2026	LRMR Larimar Therapeutics	-$0.3815	-$0.30	+$0.0815	-$0.30	N/A	N/A
7/31/2026	Q2 2026	MRNA Moderna	-$2.03	-$1.97	+$0.06	-$1.97	$102.93 million	$145.00 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
INO Inovio Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
LRMR Larimar Therapeutics	N/A	N/A	N/A	N/A	N/A
MRNA Moderna	N/A	N/A	N/A	N/A	N/A
PBYI Puma Biotechnology	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
INO Inovio Pharmaceuticals	N/A	1.00	1.00
LRMR Larimar Therapeutics	N/A	4.70	4.70
MRNA Moderna	0.09	2.29	2.18
PBYI Puma Biotechnology	N/A	2.91	2.64

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
INO Inovio Pharmaceuticals	26.79%
LRMR Larimar Therapeutics	91.92%
MRNA Moderna	75.33%
PBYI Puma Biotechnology	61.29%

Insider Ownership

Company	Insider Ownership
INO Inovio Pharmaceuticals	1.70%
LRMR Larimar Therapeutics	4.00%
MRNA Moderna	10.80%
PBYI Puma Biotechnology	22.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
INO Inovio Pharmaceuticals	320	103.40 million	101.64 million	Optionable
LRMR Larimar Therapeutics	30	103.88 million	99.73 million	Optionable
MRNA Moderna	4,700	399.24 million	356.12 million	Optionable
PBYI Puma Biotechnology	200	51.62 million	40.16 million	Optionable

INO, MRNA, PBYI, and LRMR Headlines

Recent News About These Companies

Puma Biotechnology (NASDAQ:PBYI) Stock Rating Upgraded by Wall Street Zen

August 15 at 1:53 AM | americanbankingnews.com

Puma Biotechnology (NASDAQ:PBYI) Upgraded at Wall Street Zen

August 15 at 1:53 AM | marketbeat.com

Is Puma Biotechnology (PBYI) a Great Value Stock Right Now?

August 12, 2026 | zacks.com

Puma Biotechnology (NASDAQ:PBYI) Price Target Raised to $6.00

August 10, 2026 | americanbankingnews.com

Puma Biotechnology (NASDAQ:PBYI) Issues Earnings Results, Beats Expectations By $0.15 EPS

August 7, 2026 | marketbeat.com

TD Cowen Forecasts Strong Price Appreciation for Puma Biotechnology (NASDAQ:PBYI) Stock

August 7, 2026 | marketbeat.com

PBYI Q2 Earnings & Sales Beat Estimates, 2026 Guidance Raised

August 7, 2026 | zacks.com

Puma Biotechnology, Inc. (PBYI) Q2 2026 Earnings Call Transcript

August 7, 2026 | seekingalpha.com

Puma Biotechnology Q2 Earnings Call Highlights

August 7, 2026 | marketbeat.com

Puma Biotech (PBYI) Q2 Earnings and Revenues Top Estimates

August 6, 2026 | zacks.com

Puma Biotechnology Reports Second Quarter 2026 Financial Results

August 6, 2026 | businesswire.com

Renaissance Technologies LLC Cuts Position in Puma Biotechnology, Inc. $PBYI

August 2, 2026 | marketbeat.com

Earnings Preview: Puma Biotech (PBYI) Q2 Earnings Expected to Decline

July 30, 2026 | zacks.com

Puma Biotechnology (PBYI) to Release Quarterly Earnings on Thursday

July 30, 2026 | marketbeat.com

Puma Biotechnology to Host Conference Call to Discuss Second Quarter 2026 Financial Results

July 23, 2026 | finance.yahoo.com

Douglas Hunt Sells 8,460 Shares of Puma Biotechnology (NASDAQ:PBYI) Stock

July 9, 2026 | insidertrades.com

Puma Biotechnology Shareholders Back Governance, Reject Warrant Extension

June 16, 2026 | tipranks.com

Puma Biotechnology (NASDAQ:PBYI) Director Brian Stuglik Sells 8,100 Shares

June 16, 2026 | insidertrades.com

Puma Biotechnology Stock Rises 19% in 3 Months: Here's Why

June 11, 2026 | zacks.com

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

June 3, 2026 | businesswire.com

Puma Biotechnology Reveal Hidden Strength Amid Rising Market Focus

May 17, 2026 | kalkinemedia.comK

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

INO, MRNA, PBYI, and LRMR Company Descriptions

Inovio Pharmaceuticals NASDAQ:INO

$1.20 +0.05 (+4.35%)

Closing price 04:00 PM Eastern

Extended Trading

$1.19 -0.01 (-0.92%)

As of 06:18 PM Eastern

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade dysplasia; INO-3107 for HPV-related recurrent respiratory papillomatosis and is under Phase 1/2 trial; INO-3112 for the treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma and is under Phase 2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under Phase 1b trial; INO-4800 for COVID-19 and is under Phase 3 trial; and INO-6160 for the treatment of human immunodeficiency virus and is under Phase 1 trial. Its partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations, Defense Advanced Research Projects Agency, The U.S. Department of Defense, HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter-Helm BioLogics, Thermo Fisher Scientific, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute. The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania.

Larimar Therapeutics NASDAQ:LRMR

$4.06 -0.26 (-6.02%)

Closing price 04:00 PM Eastern

Extended Trading

$4.04 -0.01 (-0.37%)

As of 06:12 PM Eastern

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc. is based in Bala Cynwyd, Pennsylvania.

Moderna NASDAQ:MRNA

$62.96 -1.50 (-2.33%)

Closing price 04:00 PM Eastern

Extended Trading

$62.96 +0.01 (+0.01%)

As of 06:16 PM Eastern

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Puma Biotechnology NASDAQ:PBYI

$9.24 +0.42 (+4.76%)

Closing price 04:00 PM Eastern

Extended Trading

$9.25 +0.01 (+0.11%)

As of 04:10 PM Eastern

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest INO, MRNA, PBYI, and LRMR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest INO, MRNA, PBYI, and LRMR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

INO, MRNA, PBYI, and LRMR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

INO, MRNA, PBYI, and LRMR Company Descriptions

Inovio Pharmaceuticals NASDAQ:INO

Larimar Therapeutics NASDAQ:LRMR

Moderna NASDAQ:MRNA

Puma Biotechnology NASDAQ:PBYI

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest INO, MRNA, PBYI, and LRMR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest INO, MRNA, PBYI, and LRMR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

INO, MRNA, PBYI, and LRMR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

INO, MRNA, PBYI, and LRMR Company Descriptions

Inovio Pharmaceuticals NASDAQ:INO

Larimar Therapeutics NASDAQ:LRMR

Moderna NASDAQ:MRNA

Puma Biotechnology NASDAQ:PBYI

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools